drugset / Trial / NCT02483208

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

NCT02483208

Phase 1 Completed 18 enrolled Bayer
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to compare the pharmacokinetics of BAY81-8973 and Advate after intravenous administration.

Timeline

Start
2015-06
Primary completion
2015-07
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ADVATE Protein / enzyme biologic 50 iu/kg Intravenous

Indications